Présentation de l'entreprise
Cibus, Inc. operates within the healthcare sector, specifically focusing on the biotechnology industry, where it develops and licenses gene-edited plant traits designed to enhance agricultural productivity. The company's core mission involves creating solutions that enable farmers to achieve higher yields while simultaneously reducing reliance on chemical inputs such as fungicides, insecticides, and fertilizers, thereby offering sustainable ingredients for various applications. As a mid-sized entity in its field, Cibus, Inc. currently maintains a market capitalization of $118.39 million and employs a workforce of 118 individuals. The annual revenue generated over the trailing twelve months stands at $3.64 million, which, when viewed against the market cap, indicates a company with a relatively small revenue base relative to its valuation, suggesting that the market price reflects significant expectations for future growth or intangible assets rather than current cash flow generation.
Santé financière
The financial performance of Cibus, Inc. over the trailing twelve months reveals a challenging operating environment characterized by significant losses relative to its sales volume. The company reported a revenue of $3.64 million, yet simultaneously recorded a net income of $-127,085,000 and an EBITDA of $-61,541,000. The substantial gap between the positive revenue figure and the deeply negative net income highlights a severe cost structure where expenses, including likely heavy research and development costs, drastically exceed the income generated from operations. This disparity is further underscored by the negative free cash flow of $-51,790,624, which indicates that the company is burning through its liquidity reserves to fund operations and growth initiatives, thereby limiting its immediate financial flexibility. The margin analysis reveals a gross margin of 100.0%, suggesting that the cost of goods sold is negligible compared to revenue, yet this is offset by an operating margin of -1273.3% and a profit margin of 0.0%, pointing to extreme overhead burdens that prevent profitability despite efficient production costs. On the balance sheet side, the company holds $9.92 million in cash but carries a substantial debt load of $267.96 million, resulting in a debt-to-equity ratio of 1227.56 that characterizes a highly leveraged position. Additionally, the current ratio of 0.72 indicates that the company's current assets are insufficient to cover its current liabilities, signaling potential short-term liquidity pressures. Finally, the return metrics demonstrate a return on equity of -221.0% and a return on assets of -12.9%, revealing that management has not yet generated returns for shareholders or asset holders, reflecting the early-stage or loss-making nature of the business model.
Évaluation de la valorisation
Valuation multiples for Cibus, Inc. present a complex picture due to the company's lack of profitability and negative earnings history. The trailing twelve-month P/E ratio is listed as N/A because there are no positive earnings to calculate a standard multiple, while the forward P/E is -7.33, which implies that analysts or models anticipate continued negative earnings in the near term. The price-to-book ratio stands at 3.64, indicating that the market values the company at a significant premium over its net book value, likely due to the high value placed on its intellectual property and patent portfolio. Alternative valuation metrics provide further insight, with a price-to-sales ratio of 32.53 and an EV/EBITDA of -5.84, suggesting that the stock is priced based on future revenue potential and strategic positioning rather than current earnings power. In terms of trading range, the stock has seen a 52-week high of $4.19 and a 52-week low of $1.09, meaning the current price sits within a wide volatility band that reflects high investor sentiment swings. The beta of 1.93 indicates that the stock price is nearly twice as volatile as the broader market, exposing investors to substantial fluctuations that are magnified during periods of market stress.
Growth & Income
The growth trajectory and income profile of Cibus, Inc. are defined by revenue contraction rather than expansion in the recent period. The revenue growth year-over-year is -12.8%, while earnings growth is listed as N/A due to the absence of positive earnings in the prior period, indicating that the company is not currently growing its bottom line and is instead managing a decline in sales. Since the company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it does not distribute cash to shareholders; instead, it retains earnings—however negative they may be—to reinvest into its biotechnology research and development efforts. The overall growth and income profile is one of negative revenue momentum and a complete lack of income distribution, which is typical for a biotechnology firm in a development phase that prioritizes capital expenditure over shareholder returns. The company's ability to reverse the revenue decline and utilize its cash reserves to fund operations will be critical in determining if it can eventually transition from a loss-making entity to a profitable one.